Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10132422 | 1.00 | PIK3CG (0.72) | PIK3CGMAPT | |
| SCHEMBL15180091 | 0.88 | PIK3CG (0.74) | PIK3CGMAPT | |
| SCHEMBL10044542 | 0.87 | PIK3CG (0.57) | PIK3CG | |
| SCHEMBL3582269 | 0.83 | PIK3CG (1.00) | PIK3CG | |
| SCHEMBL14094957 | 0.83 | PIK3CG (1.00) | PIK3CG | |
| SCHEMBL4285724 | 0.83 | PIK3CG (0.66) | PIK3CG | |
| SCHEMBL3586252 | 0.82 | PIK3CG (1.00) | PIK3CG | |
| SCHEMBL4287398 | 0.80 | PIK3CG (0.53) | PIK3CGMAPT | |
| SCHEMBL4288292 | 0.80 | PIK3CG (0.59) | PIK3CGMAPT | |
| SCHEMBL4294735 | 0.80 | PIK3CG (0.52) | PIK3CGMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2630129-B1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2016-10-26 | — | — | EP | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-8895559-B2 | Quinoxalines derivatives and pharmaceutical compositions and kits | MERCK PATENT GMBH (DE) | 2014-11-25 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | MERCK PATENT GMBH (DE) | 2013-08-22 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | MERCK SERONO S.A. GENEVA (CH) | 2013-08-15 | — | — | US | disclosed |
| WO-2012052420-A1 | METHOD FOR PREPARING SUBSTITUTED N-(3-AMINO-QUINOXALIN-2-YL)-SULFONAMIDES AND THEIR INTERMEDIATES N-(3-CHLORO-QUINOXALIN-2-YL)SULFONAMIDES | MERCK SERONO S.A. GENEVA (CH) | 2012-04-26 | — | — | WO | disclosed |
| WO-2012052102-A1 | QUINOXALINE DERIVATES | MERCK PATENT GMBH (DE) | 2012-04-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130217670-A1 | QUINOXALINE DERIVATIVES | PIK3R5, NQO2, PIK3R1 | PIK3CG 8/4885MAPT 4120/4885 |
| US-20130211076-A1 | Method for preparing substituted N-(3-amino-quinoxalin-2-yl)-sulfonamides and their intermediates N-(3-chloro-quinoxalin-2-yl)-sulfonamides | STS, NQO2, ASNS | PIK3CG 2294/4885MAPT 4392/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.